Categories: EHRNews

Acuitive Technologies introduces Citregraft, a unique bone graft substitute designed to bind proteins and enhance regeneration

ALLENDALE, N.J., Nov. 20, 2025 (GLOBE NEWSWIRE) — Acuitive Technologies® commercializes Citregraft™, with its first use in a surgical case, performed on November 4th, 2025.

Bone graft substitutes are used to repair defects from trauma, infection, tumor removal, and reconstructive surgery. However, poor handling, low biological activity, variable resorption rate, and inadequate integration limit their effectiveness.

Leveraging the benefits of citrate in bone anatomy and physiology, Acuitive Technologies developed Citregen®, a citrate-based polymer technology that mimics natural bone chemistry and supplies the energy needed for regeneration. Exclusively made with Citregen and bioactive glass, Citregraft is a highly porous and bioactive synthetic bone graft substitute designed to interact with proteins to regenerate bony voids within the skeletal system.

Citregraft benefits include:

  •  Bioactive formulation to improve graft integration
  •  Easily morselized to fill and hold its position within irregular defects
  •  Absorbs 5 times its weight in fluids
  •  Synergizes with bone marrow aspirate (BMA) to bind proteins
  • Citrate increases cell energy for tissue regeneration

Citregraft was easily morselized to fill my tibial harvest site during BPTB ACL reconstruction. After soaking it in saline, it readily absorbed blood and growth factors from the harvest site and conformed perfectly to the defect,” said Robin Gehrmann, MD.

Citregraft overcomes the limitations of conventional bone graft substitutes by improving handling, liquid uptake, and protein binding. Its demonstrated bioactivity and ability to bind proteins establish Citregraft as a viable option for surgeons seeking innovative solutions for bone repair and regeneration.

Media Contact
Thomas McCarthy
Acuitive Technologies, Inc.
tmccarthy@acuitivetech.com
https://www.acuitivetech.com/

Data on file, TM251008, at Acuitive Technologies Inc., Allendale, NJ, USA

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/233ecf43-c685-4d77-ba95-b1a49b14eecb

Staff

Recent Posts

TempraMed Launches New Product, VIVI Cap Smart, Expanding Its Portfolio to Include a Digital Health Offering

Integrated smart technology builds on TempraMed's proven VIVI platform, providing robust Temperature control with medication…

2 hours ago

More Than a Meal Plan: The Clinical Impact of a Kidney Dietitian

NORTHAMPTON, MA / ACCESS Newswire / December 26, 2025 / Specialized nutrition experts are key…

4 hours ago

President Trump’s Executive Marijuana Action Exposes the Truth-How the DEA Delayed Medicine While Protecting Everything Else

"Despite clear congressional mandates and FDA authorization, the Drug Enforcement Administration failed to act within…

4 hours ago

From Follower to Force: China’s Biotech Sector Enters the Global Clinical Mainstream

WASHINGTON, Dec. 26, 2025 /PRNewswire/ -- Over the past decade, China has evolved from a biotechnology…

7 hours ago

Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split

SEATTLE, WA / ACCESS Newswire / December 26, 2025 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a…

10 hours ago